[1] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 4: 1-10.
[2] Butler L, Pilkington K. Chinese herbal medicine and depression: the research evidence. Evid Based Complement Alternat Med. 2013; Article ID 739716.
[3] Moein E, Hajimehdipoor H, Hamzeloo-Moghadam M, Choopani R, Toliyat T. Review of an aloe-based formulation used in Iranian traditional medicine. Jundishapur J Nat Pharm Prod. 2016; Article ID e40193.
[4] Rabiei Z, Rabiei S. A review on antidepressant effect of medicinal plants. Bangladesh J Pharmacol. 2017; 12(1): 1-11.
[5] Perviz S, Khan H, Pervaiz A. Plant alkaloids as an emerging therapeutic alternative for the treatment of depression. Front Pharmacol. 2016; 7: 1-7.
[6] Zarghami M, Chabra A, Azadbakht M, Khalilian A, Hoseini A. Antidepressant effect of Asperugo procumbens L. in comparison with fluoxetine: a randomized double blind clinical trial. Res J Pharmacogn. 2018; 5(3): 15-20.
[7] Nazem Jahan MA. Exir-e-azam. Tehran: Iran University of Medical Sciences, 2008.
[8] [7] Nazem Jahan MA. Qarabadin-e-Azam. Tehran: Research Institute for Islamic & Complementary Medicine, 2003.
[9] Arzani MA. Tebb-e-Akbari. Tehran: Institute of Medical History, Islamic and Complementary Medicine, Iran University of Medical Sciences, 2005.
[10] National Research Council. Guide for the care and use of laboratory animals. Washington D.C.: National Academies Press, 2010.
[11] Iranian Herbal Pharmacopoeia Committee. Iranian herbal pharmacopoeia. Tehran: Ministry of Health and Medical Education Publications, Food and Drug Administration, 2002.
[12] The British Pharmacopoeia Commission. British pharmacopoeia. London: The Stationary Office, 2011.
[13] Committee for the Unani Pharmacopoeia of India. Unani pharmacopoeia of India. New Delhi: Department of AYUSH, Ministry of Health & Family Welfare, 2007.
[14] World Health Organization. Quality control methods for medicinal plant materials. Geneva: WHO Press, 2011.
[15] Hamzeloo-Moghadam M, Danaifar N, Mostafavi SA, Hajimehdipoor H. Formulation and quality control of Prunus domestica syrup, prepared according to Iranian traditional medicine. Res J Pharmacogn. 2015; 2(2): 13-17.
[16] Halip A, Imam G, Yusup A. The effect of abnormal savda munziq (ASMq) on biological syndromes of depression animal models. [Accessed 2017]. Available fromhttp://en.cnki.com.cn/Article_en/CJFDTotal-XJYY201703034.htm.
[17] Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005; 29(4-5): 571-625.
[18] Mahmoudi E, Faizi M, Hajiaghaee R, Razmi A. Alteration of depressive-like behaviors by Psilocybe cubensis alkaloid extract in mice: the role of glutamate pathway. Res J Pharmacogn. 2018; 5(2): 17-24.
[19] Voiculescu S, Rosca A, Zeca V, Zagrean L, Zagrean A. Impact of maternal melatonin suppression on forced swim and tail suspension behavioral despair tests in adult offspring. J Med Life. 2015; 8(2): 202-206.
[20] Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacol. 1985; 85(3): 367-370.
[21] Sayyah M, Boostani H, Pakseresht S, Malaieri A. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(8): 1513-1516.
[22] Saki K, Bahmani M, Rafieian-Kopaei M. The effect of most important medicinal plants on two important psychiatric disorders (anxiety and depression) a review. Asian Pac J Trop Dis. 2014; 7(S1): 34-42.
[23] López V, Martín S, Gómez-Serranillos MP, Carretero ME, Jäger AK, Calvo MI. Neuroprotective and neurological properties of Melissa officinalis. Neurochem Res. 2009; 34(11): 1955-1961.
[24] Taiwo AE, Leite FB, Lucena GM, Barros M, Silveira D, Silva MV, Ferreira VM. Anxiolytic and antidepressant-like effects of Melissa officinalis (lemon balm) extract in rats: influence of administration and gender. Indian J Pharmacol. 2012; 44(2): 189-192.
[25] Mokhtarifar N, Sharif B, Naderi N, Mosaddegh M, Faizi M. Evaluation of anti-depressant effects of Cuscuta chinensis in experimental models. Res Pharm Sci. 2012; 7(5): 826.
[26] Firoozabadi A, Zarshenas MM, Salehi A, Jahanbin S, Mohagheghzadeh A. Effectiveness of Cuscuta planiflora Ten. and Nepeta menthoides Boiss. &Buhse in major depression: a triple-blind randomized controlled trial study. J Evid Based Complement Alternat Med. 2015; 20(2): 94-97.
[27] Cheng D, Murtaza G, Ma S, Li L, Li X, Tian F, Zheng J, Lu Y. In silico prediction of the anti-depression mechanism of a herbal formula (Tiansi liquid) containing Morinda officinalis and Cuscuta chinensis. Molecules. 2017; 22(10): 1-16.
[28] Aslam M, Sultana N. Vitis vinifera juice ameliorates depression-like behavior in mice by modulating biogenic amine neurotransmitters. Bangladesh J Pharmacol. 2015; 10(4): 753-758.
[29] Solanki N, Alkadhi I, Atrooz F, Patki G, Salim S. Grape powder prevents cognitive, behavioral, and biochemical impairments in a rat model of posttraumatic stress disorder. Nutr Res. 2015; 35(1): 65-75.
[30] Tavakkoli-Kakhki M, Motavasselian M, Mosaddegh M, Esfahani MM, Kamalinejad MM, Nematy M. Food-based strategies for depression management from Iranian traditional medicine resources. Iran Red Crescent Med J. 2014; 16(2): 1-5.
[31] Yousofpour M, Kamalinejad M, Esfahani MM, Iran-nejad S, Shorofi SA, Shams J. Non-pharmacological interventions for depression in Persian medicine. Tang. 2015; 5(4): 1-7.
[32] Thakare VN, Patil RR, Oswal RJ, Dhakane VD, Aswar MK, Patel BM. Therapeutic potential of silymarin in chronic unpredictable mild stress induced depressive-like behavior in mice. J Psychopharmacol. 2018; 32(2): 223-235.
[33] Hong LZ, Huang KF, Hung SW, Kuo LT. Chronic fluoxetine treatment enhances sympathetic activities associated with abnormality of baroreflex function in conscious normal rats. Eur J Pharmacol. 2017; 811: 164-170.
[34] Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004; 6(4): 159-166.